Design, synthesis, and biological evaluation of tyrcinnamine derivatives as bactericides Authors: Lijie Zheng, Baoyue Wei, Ji Pang, Yichen Yang, Mingjie Zhang, Ke Ma, Shan Lu Published: 2026 ABSTRACT AbstractStructural modification of bioactive natural products plays a vital role in the development of new drugs. Herein, we report the design and synthesis of twelve new tyrcinnamin derivatives (6a-8a, 6b-7b, 6c-8c, 10, and 13–15) using tyrcinnamin methyl ester (2) as a lead. In vitro biological investigation indicated that, unlike the lead (2), which is a bacteriostat, 14 exhibited significant bactericidal activity against Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA). Mechanistic studies indicated that the bactericidal effect of 14 might induced by the membrane-disrupting and reactive oxygen species (ROS) generation. In vivo investigation with a Galleria mellonella larvae infection model revealed that 14 significantly inhibited the growth of MRSA, therefore enhancing the survival rate of the MRSA-infected G. mellonella larvae. The strong antibacterial activity, excellent safety profile, and good solubility of 14 make it a promising candidate for the development of new bactericides. Introduction Given the increasing prevalence of drug resistance in bacterial infections, there is an urgent need to develop new antibacterial agents with new structures and new modes of action.1,2 A report recently released by the World Health Organisation (WHO) concluded that although the number of antibacterial agents in the clinical pipeline increased from 80 in 2021 to 97 in 2023, there remains an urgent demand for new agents for serious infections induced by drug resistance. Antibiotics are generally classified as bactericides and bacteriostats, based on their modes of action.3,4 Bactericides directly kill bacteria by disrupting cell walls, membranes, or DNA synthesis, leading to irreversible death. Such a property makes them suitable for severe infections. The representative bactericides include penicillin, vancomycin, and fluoroquinolones. On the other hand, bacteriostatic agents mainly inhibit bacterial growth and rely on the host immune system for pathogen clearance, therefore being suitable for mild-to-moderate infections. Azithromycin, clindamycin, and linezolid are widely used bacteriostats clinically. A recent perspective argued that it was highly challenging to predict whether a particular antibacterial would act as a bacteriostat or a bactericide in patients since the drug’s action might be contingent on factors such as bacterial load and interaction with the immune system at the infection site. Therefore, some bacteriostats may serve as valuable options in the treatment of severe infections.4 In any case, the development of new antibiotics, no matter they are bacteriostats or bactericides, will strongly contribute to the anti-infective therapy. Natural products serve as crucial sources for discovering new antibiotics.5 We previously reported the isolation and total synthesis of tyrcinnamin (1), a natural hybrid molecule of cinnamic acid derivative with L-tyrosine.6 The total synthesis of tyrcinnamin (1) led to the discovery of tyrcinnamin methyl ester (2), which exhibited significant bacteriostatic activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), and an excellent safety profile.6 Herein, we report a further comprehensive structure-activity relationship study by using tyrcinnamin methyl ester (2) as a lead compound. Several classic strategies in medicinal chemistry, including cyclisation, substitution, conformation transformation, and chain extension, were applied to explore new candidates with stronger antibacterial activity (Figure 1). In vivo assay with a Galleria mellonella larvae infection model was applied to evaluate the antibacterial activity and safety of the hit compound. Design of the new tyrcinnamine derivatives. Results and discussion Design, synthesis, and antibacterial activity We previously reported that tyrcinnamin methyl ester (2) exhibited much stronger antibacterial activity than tyrcinnamin (1), suggesting that the methyl ester has a significant effect on its antibacterial bioactivity. To further investigate the effect of the ester, we replaced the methyl ester with ethyl ester, t-butyl ester, and methyl amide, and synthesised the corresponding compounds 6a-8a (Scheme 1A). Surprisingly, these compounds showed no effect on the growth of S. aureus even at 40 μg/mL, indicating the crucial role of the methyl ester on the activity (Table 1). Synthetic routes of derivatives 6a-8a (A), 6b-7b (A), 6c-8c (A), 10 (B), 13 (C), 14 (D), and 15 (E). (a) Lindlar catalyst, MeOH, H2, r.t., 24 h; (b) LiOH, EtOH, H2O, r.t., 16 h; (c) Corresponding L-amino acid esters or amides, EDCl, pyridine, r.t., overnight; (d) SOCl2, MeOH, −20 °C to r.t. Table 1.In vitro antibacterial activity of tyrcinnamin derivatives 2, 6a-8a, 6b-7b, 6c-8c, 10, and 13–15. Penicillin G and vancomycin were used as positive controls.CompoundsMIC values (μg/mL)S. aureus ATCC6538B. subtilis ATCC6633MRSA ATCC 43300MRSA 1593*E. faecalis ATCC 51299 2 55––– 6a > 40> 40––– 7a > 40> 40––– 8a > 40> 40––– 6b 1010––– 7b > 40> 40––– 6c > 40> 40––– 7c > 40> 40––– 8c > 40> 40––– 10 > 40> 40––– 13 5> 40––– 14 55204040 15 1010–––Penicillin G0.053> 0.5––Vancomycin––1.00.515*Environmentally isolated multidrug-resistant strain. In vitro antibacterial activity of tyrcinnamin derivatives 2, 6a-8a, 6b-7b, 6c-8c, 10, and 13–15. Penicillin G and vancomycin were used as positive controls. *Environmentally isolated multidrug-resistant strain. The effect of the double bond of the pentenyl side chain on the antibacterial activity was next investigated. Compound 4a was synthesised through the hydrogenation of 3 under the catalysis of the Landlar catalyst.6 However, the yield was moderate (50.2%). A detailed analysis of the reaction products via LC-MS revealed that another two byproducts, 4b (8.3%) and 4c (33.2%), were generated during the hydrogenation (Scheme 1A, Supplementary Fig. S1). Although it is well known that Landlar catalyst usually gives trans-product, the above result provides evidence that a considerable amount of cis-product may be generated under the same conditions. Byproducts are usually unwanted in organic synthesis. However, every coin has two sides. Such a side reaction offered us an opportunity to obtain the trans derivative 4b and the reduced derivative 4c conveniently for the SAR study without re-designing new synthetic routes. Compounds 6b-7b and 6c-8c were finally synthesised from 4b and 4c, respectively (Scheme 1A). However, although the trans derivative 6b maintained antibacterial activity with a MIC value of 10 μg/mL, it was not as potent as the lead (2) (MIC: 5 μg/mL) (Table 1). The reduction of the double bind (6c) resulted in a complete loss of the activity. These results collectively indicated that reduction and conformation transformation of the cis double bond of the pentenyl side chain negatively affected the antibacterial activity. The cyclisation strategy is widely used in drug design.[7,8] The molecular confirmation restriction via cyclisation is expected to increase the binding affinity of the molecule to the target protein. In view of this, we designed and synthesised compound 10 from 2-naphthoic acid (Scheme 1B). However, such a strategy did not give any positive effect (Table 1), suggesting that the free pentenyl side chain was required for the antibacterial activity. Homo-L-tyrosine has been reported to exhibit antibacterial activity against gram-positive and gram-negative bacteria.9 We next replaced the tyrosine moiety of the lead (2) with homo-L-tyrosine and synthesised compound 13 (Scheme 1C), hoping that homo-L-tyrosine could enhance its antibacterial activity. However, no enhancement of antibacterial activity was observed in 13. We finally decided to modify the phenol ring in the tyrosine moiety of the lead (2). In our previous study, replacement of the tyrosine moiety with phenylalanine led to the loss of the antibacterial activity, suggesting the important role of the para-OH group.6 Therefore, we replaced the L-tyrosine moiety in 2 with levodopa (L-DOPA), which has two hydroxyl groups at meta- and para-positions, and synthesised compound 14 (Scheme 1D). Antibacterial assay revealed that 14 exhibited antibacterial activity comparable to that of the lead (2) against the two gram-positive bacteria with a MIC value of 5 μg/mL (Table 1). The impact of the meta-OH group was further validated by derivative 15 (Scheme 1E), which contains a meta-OH as well but has a saturated side chain. A comparison of the antibacterial activity of 6c (MIC: > 40 µg/mL) and 15 (MIC: 10 µg/mL) revealed the positive impact of the meta-OH group on the antibacterial activity. Further evaluation with a standard MRSA strain (ATCC 43300), an environmentally isolated multidrug-resistant MRSA strain (1593), and a highly drug-resistant Enterococcus faecalis strain (ATCC 51299) validated the antibacterial activity of 14 against the drug-resistant Gram-positive bacteria (MIC: 20–40 μg/mL). Based on the above studies, the comprehensive structure-activity relationship of tyrcinnamine derivatives was finally summarised as below (Figure 2). Summary of the structure-activity relationship of tyrcinnamine derivatives. Mechanistic study Colony-forming unit assay (CFU) was used for detecting the number of viable microbial cells after treatment with antibiotics.10 To investigate the modes of action of 2 and 14, a CFU assay was carried out. The result indicated that 14 acted as a bactericide, whereas the 2 was obviously a bacteriostat. Although 2 strongly inhibited the growth of S. aureus at 40 μg/mL, the residual bacteria resumed growth upon re-seeding in the fresh culture medium, reaching robust proliferation within 36 h. In contrast, 14 eradicated nearly all S. aureus at the same concentration, with no detectable regrowth within 36 h after re-seeding (Figure 3A). To further quantify the bactericidal efficacy of 14, the bactericidal kinetics were assessed with MRSA (ATCC 43300) (Figure 3B). It was evident that 14 eliminated nearly all the MRSA within six hours at 4 × MIC (80 μg/mL), resulting in no colony observed after re-seeding. The minimum bactericidal concentration (MBC) value was then determined as 80 μg/mL (Figure 3C). Given the increasingly serious problem of antibiotic resistance, we also evaluated the mutant prevention concentration (MPC) value of 14 with a high concentration of MRSA (ATCC 43300, 1 × 1010 CFU/mL, Figure 3D). Surprisingly, the MPC value of 14 (80 µg/mL) is almost identical to its MBC value, suggesting its low risk of inducing resistance. (A) The colony-forming unit assay. Images of S. aureus colonies exposed to compound 2 or 14 and re-seeded for additional 36 h. Penicillin G (0.05 μg/mL) was used as a positive control. (B) The bactericidal kinetics of 14. (C) The evaluation of the MBC value of 14. The concentration of the MRSA for the test was 1 × 106 CFU/mL. (D) The evaluation of the MPC value of 14. The concentration of the MRSA for the test was 1 × 1010 CFU/mL. Vancomycin (1.0 μg/mL) was used as a positive control. To further validate the distinct modes of action of 2 and 14, we investigated their effects on the membrane integrity using a scanning electron microscope (SEM) (Figure 4A). Compound 2, as a bacteriostat, does not induce significant morphological damage within 2 h at 40 μg/mL (2 × MIC). In contrast, obvious membrane shrinkage was observed in the 14-treated MRSA at the same concentration (2 × MIC). Enhancing the concentration to 4 × MIC resulted in the more severe shrinkage and surface collapse. Although further investigations, such as the transmission electron microscopy (TEM) experiment, might be needed for validation of the mode of action, the above results collectively reveal that 14, as a bactericide, exerts a potent membrane-disrupting effect. Mechanistic study of 14. (A) Scanning electron microscope (SEM) images of the cell membrane of MRSA (ATCC 43300) cells. DMSO was used as a negative control. The cells were treated with 2 at a concentration of 40 μg/mL (2 × MIC) and with 14 at concentrations of 40 (2 × MIC) and 80 (4 × MIC) μg/mL, respectively. Scale bar: 2 μm. (B) Intracellular ROS generation after treatment with 14. DMSO was used as a negative control. Rosup was used as a positive control. n = 3; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Reactive oxygen species (ROS) production of antibiotics has recently been recognised as a contribution to bacterial killing.11,12 Given the catechol moiety in the structure of 14, we next investigated the generation of ROS after treatment with 14 using a fluorescent probe (DCFH-DA). It is evident that 14 induced the generation of ROS in a dose-dependent manner (Figure 4B), suggesting that its ‌bactericidal effect might be correlated with the induction of oxidative stress. Antibacterial assay in vivo Compound 14 was selected for further evaluation in vivo. Animal studies usually require proper solubility of the test compounds.13 Therefore, we first evaluated the solubility of 14 in phosphate buffer saline (PBS, pH 7.4). The result indicated that the solubility of 14 in PBS is quite limited (4.9 μg/mL). To enhance its solubility, we employed the commonly used solubilising agents, including PEG300 and Tween-80. In the vehicle consisting of 3% DMSO, 20% PEG300, 5% Tween-80, and 72% saline, 14 dissolved readily (> 6 mg/mL), indicating a good solubility for in vivo study. An insect model of MRSA infection using Galleria mellonella larvae was then set up to evaluate the protective efficacy of 14 (Figure 5A) in vivo. G. mellonella larvae were widely used as an insect model for preliminary screening of antibiotics owing to their innate immune system characteristics similar to mammals.13–15 As expected, 14 significantly increased the survival rates of G. mellonella larvae at both low (25 mg/kg) and high (50 mg/kg) doses. The protective efficacy at the high dose (50 mg/kg) was even comparable to that of the positive control, vancomycin (30 mg/kg)13 (Figure 5B and 5C), demonstrating the strong bactericidal effect of 14 in vivo. Furthermore, the high survival rate of Galleria mellonella larvae at high dose (50 mg/kg) also suggested the excellent safety profile of 14.[16,17] Further safety evaluation revealed that 14 exhibited no significant cytotoxicity against human HepG2 cells and haemolytic effect in rabbit erythrocytes at a concentration of 50 μM (Supplementary Fig. S2A and S2B).[18,19] Taken together, although further chemical modification and biological evaluations are needed for stronger antibacterial activity and better safety profile, the present findings suggest that 14 may serve as a promising lead for developing new antibiotics. In vivo antibacterial activity of 14. (A) Schematic overview of the G. mellonella larvae infection and treatment protocol. (B) Survival curves of infected G. mellonella larvae over 120 h after treatment with 14 or vancomycin. Both uninfected group (orange) and vehicle-treated group (black) were set as controls. n = 10; ****p ≤ 0.0001. (C) Images of G. mellonella larvae in all groups at 120 h post-infection. Yellowish white larvae were alive, whereas black or brown larvae were dead. Tyrosinase activation/inhibition assay in vitro Since 2 was also reported as a strong tyrosinase activator (> 300% at 0.4 mg/mL),6 we also evaluated the effect of 14 on the function of mushroom tyrosinase. Surprisingly, although the L-DOPA moiety in 14 is exactly a substrate for tyrosinase, the whole molecule exhibited little effect on mushroom tyrosinase, suggesting the significant effect of the meta-OH on the interaction of 14 with the enzyme (Figure 6A). Such an effect was then investigated by molecular docking analysis.18 L-DOPA and 2 were used as controls. The result indicated that 14 does not occupy the L-DOPA binding sites located on the surface and in the catalytic centre, therefore exhibiting less effect on the function of the enzyme (Figure 6B). (A) Effects of 2 and 14 on the mushroom tyrosinase activity in vitro. Kojic acid was used as a positive control. (B) Docking analysis of mushroom tyrosinase (AbPPO3, PDB ID: 2Y9W) with 14 (green) and L-DOPA (blue), respectively. Silver ribbon: AbPPO3; gray ribbon: lectin-like subunit, brown ball: copper(II) ion. Conclusion In conclusion, by leveraging the side reaction of Lindlar-catalyzed hydrogenation, we designed and synthesised twelve tyrcinnamin derivatives (6a-8a, 6b-7b, 6c-8c, 10, 13–15) using tyrcinnamin methyl ester (2) as a lead. A comprehensive structure-activity relationship study revealed that the methyl ester, the free cis-pentenyl side chain, and the para-tyrosine moiety are crucial to the antibacterial activity (Figure 2). Extension of the carbon chain in the L-tyrosine moiety (homo-L-tyrosine moiety) preserved the antibacterial efficacy against S. aureus (MIC: 5 μg/mL), but resulted in a complete loss of the activity against B. subtilis (> 40 μg/mL). Induction of a meta-OH group did not alter the MIC value but shifted the antibacterial action from bacteriostasis (2) to bactericidal action‌ (14), leading to almost complete elimination of MRSA. The mechanistic studies revealed that the potent bactericidal effect of 14 might be correlated with the membrane disruption and ROS-induced oxidative stress. In vivo experiment with G. mellonella larvae infection model demonstrated that 14 exhibited not only strong anti-MRSA activity, which was comparable to vancomycin, but also an excellent safety profile at a high dose. Moreover, the induction of the meta-OH also significantly changed the binding mode to mushroom tyrosinase, consequently leading to a diminished impact of 14 on the enzymatic activity. Given the significant impact of the meta-OH group and the side chain observed in the comprehensive structure-activity relationship, future investigations should prioritise the introduction of polar substitutions, such as amino and carboxyl groups, on the tyrosine moiety and the variations in the length of the side chain. The development of both the lead (2) and the hit (14) demonstrates the advantage of structural modification in the discovery of new bioactive natural product derivatives.20–22 Compound 14 may serve as a promising bactericide that is applicable in pharmaceuticals, agriculture, and cosmetics. Experimental section General experimental procedures All reagents and solvents were purchased from commercial suppliers (Adamas, Shanghai, China, and Greagent, Beijing, China) and used as received without further drying or purification. 1D and 2D NMR spectra were recorded at 25 °C on a Bruker Avance III HD 400 NMR spectrometer. Mass and high-resolution mass spectrometry (HRMS) spectra were obtained on an Agilent 1260–6120 LC/MS spectrometer or Shimazu LCMS Qtof spectrometer. Analytical and preparative thin-layer chromatography was performed on silica gel (200–300 mesh) GF/UV 254 plates, and the chromatograms were visualised under UV light at 254 nm. Analytical and preparative reversed-phase HPLC (RPLC) were conducted on a Shimadzu Prominence HPLC system using a YMC Hydrosphere C18 analytical column (3 μm, 120 Å, 150 × 4.60 mm) and a YMC Hydrosphere C18 preparative column (5 μm, 120 Å, 150 × 10 mm). Synthesis of compounds 5a-5c Compound 3 (3.5 g, 0.015 mol) and Lindlar catalyst (3.5 g, 100% wt) were mixed in 100 ml MeOH. The mixture was stirred under H2 gas (1 atm) for 24 h and then filtered. The filtrate was concentrated in vacuum, and the residue was purified by flash column (petroleum ether: ethyl acetate = 200:1) to yield 4a (1.77 g, 50.24%) as a yellow oil, and another two byproducts 4b (0.29 g, 8.29%) and 4c (1.17 g, 33.17%). Compound 4a (0.0018 mol) was next dissolved in the solution of EtOH (10 ml), LiOH·H2O (0.63 mg, 0.015 mol), and H2O (5 ml), respectively. The mixture was stirred at room temperature overnight and then washed with ethyl acetate. The 1 N HCl was then added dropwise to the water layer to adjust the pH to 3–4. The mixture was then extracted with ethyl acetate three times, and the organic layer was dried with anhydrous Na2SO4. The solution was then filtered, and the filtrate was concentrated under vacuum to yield a yellow solid. The crude product was washed with petroleum ether twice to yield compound 5a as a pale white powder. Compounds 5b and 5c were also synthesised using an identical procedure. Compound 5a: 1H NMR (ppm, 400 MHz, CD3OD): δ 12.42 (s, 1H), 7.78 (d, J = 7.6, 1H), 7.71 (d, J = 16.0, 1H), 7.40 (t, J = 7.3, 1H), 7.32 (t, J = 7.3, 1H), 7.20 (d, J = 7.5, 1H), 6.59 (d, J = 11.4, 1H), 6.46 (d, J = 15.9, 1H), 5.85 (dt, J = 11.5, 7.4, 1H), 1.95 (qd, J = 7.4, 1.7, 2H), 1.36 (m, 2H), 0.80 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 168.0, 142.1, 138.0, 134.9, 132.7, 130.2, 130.2, 127.9, 127.4, 127.0, 120.4, 30.5, 22.5, 14.1; ESIMS [M + H]+ m/z 217.0 (calcd. 217.1 for C14H17O2). Compound 5b: 1H NMR (ppm, 400 MHz, CD3OD): δ 8.02 (d, J = 15.9, 1H), 7.58 (d, J = 7.8, 1H), 7.44 (d, J = 7.3, 1H), 7.33 (t, J = 7.5, 1H), 7.25 (t, J = 7.6, 1H), 6.73 (d, J = 15.6, 1H), 6.36 (d, J = 15.9, 1H), 6.10 (dt, J = 15.6, 7.0, 1H), 2.26 (qd, J = 7.2, 1.5, 2H), 1.55 (m, 2H), 1.00 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 171.1, 143.7, 139.5, 136.4, 133.4, 131.0, 128.4, 128.2, 128.2, 127.9, 121.6, 36.4, 23.5, 14.0; ESIMS [M + H]+ m/z 217.1 (calcd. 217.1 for C14H17O2). Compound 5c: 1H NMR (ppm, 400 MHz, CD3OD): δ 8.01 (d, J = 15.8, 1H), 7.61 (dd, J = 8.1, 1.5, 1H), 7.29 (t, J = 7.4, 1H), 7.21 (t, J = 7.1, 1H), 7.20 (d, J = 7.6, 1H), 6.38 (d, J = 15.8, 1H), 2.74 (t, J = 7.8, 2H), 1.56 (m, 2H), 1.35 (m, 4H), 0.90 (t, J = 7.1, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 170.7, 143.7, 134.0, 131.2, 130.4, 129.8, 127.5, 127.4, 127.0, 34.2, 32.6, 32.6, 23.5, 14.3; ESIMS [M + H]+ m/z 219.1 (calcd. 219.1 for C14H17O2). Synthesis of compounds 6a-8a In general, to a solution of pyridine (1.5 ml) was added the corresponding L-amino acid esters or amide (0.070 mmol), 5a (15 mg, 0.069 mmol), and EDCl (14.59 mg, 0.076 mmol). The mixture was stirred at room temperature overnight, and then the pH was adjusted to 3–4 with 1 N HCl. The mixture was extracted with ethyl acetate and concentrated under vacuum. The residue was purified by preparative reversed-phase HPLC (acetonitrile: H2O = 55%) to afford compounds 6a-8a, respectively. Compound 6a: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.75 (d, J = 15.8, 1H), 7.64 (d, J = 7.0, 1H), 7.32 (t, J = 7.3, 1H), 7.27 (t, J = 7.1, 1H), 7.19 (d, J = 7.4, 1H), 7.04 (d, J = 8.5, 2H), 6.71 (d, J = 8.5, 2H), 6.59 (d, J = 15.8, 1H), 6.55 (d, J = 11.4, 1H), 5.83 (dt, J = 11.4, 7.4, 1H), 4.70 (dd, J = 8.1, 6.3, 1H), 4.14 (q, J = 7.1, 2H), 3.07 (dd, J = 13.9, 6.2, 1H), 2.95 (dd, J = 13.9, 8.2, 1H), 1.98 (qd, J = 7.5, 1.6, 2H), 1.39 (m, 2H), 1.21 (t, J = 7.1, 3H), 0.83 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 173.3, 168.4, 157.4, 140.8, 139.4, 135.8, 134.5, 131.2, 131.2, 131.0, 130.3, 128.7, 128.3, 128.2, 127.2, 122.0, 116.3, 116.3, 62.3, 55.9, 37.9, 31.6, 23.6, 14.4, 14.1; HRMS (ESI) [M + H]+ m/z 408.2217 (calcd. for C25H30NO4, 408.2175). Compound 7a: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.75 (d, J = 15.8, 1H), 7.65 (d, J = 7.4, 1H), 7.32 (t, J = 7.4, 1H), 7.27 (t, J = 7.5, 1H), 7.19 (d, J = 7.4, 1H), 7.06 (d, J = 8.5, 2H), 6.71 (d, J = 8.5, 2H), 6.60 (d, J = 15.8, 1H), 6.56 (d, J = 11.7, 1H), 5.83 (dt, J = 11.5, 7.4, 1H), 4.60 (dd, J = 7.9, 6.7, 1H), 3.03 (dd, J = 13.9, 6.7, 1H), 2.93 (dd, J = 13.9, 8.0, 1H), 1.99 (qd, J = 7.5, 1.6, 2H), 1.41 (s, 9H), 1.39 (m, 2H), 0.84 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 172.5, 168.4, 157.4, 140.7, 139.4, 135.8, 134.5, 131.4, 131.4, 131.0, 130.2, 128.8, 128.3, 128.2, 127.2, 122.1, 116.2, 116.2, 82.9, 56.4, 38.0, 31.6, 28.2, 28.2, 28.2, 23.6, 14.1; HRMS (ESI) [M + H]+ m/z 434.2325 (calcd. for C27H32NO4, 434.2331). Compound 8a: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.73 (d, J = 15.8, 1H), 7.64 (d, J = 7.6, 1H), 7.33 (t, J = 7.3, 1H), 7.27 (t, J = 7.5, 1H), 7.19 (d, J = 7.5, 1H), 7.06 (d, J = 8.5, 2H), 6.70 (d, J = 8.5, 2H), 6.58 (d, J = 15.7, 1H), 6.56 (d, J = 11.3, 1H), 5.84 (dt, J = 11.5, 7.4, 1H), 4.58 (dd, J = 8.1, 6.7, 1H), 3.03 (dd, J = 13.8, 6.7, 1H), 2.86 (dd, J = 13.8, 8.1, 1H), 2.68 (s, 3H), 1.99 (qd, J = 7.5, 1.6, 2H), 1.39 (m, 2H), 0.84 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 174.2, 168.3, 157.3, 140.6, 139.4, 135.8, 134.5, 131.2, 131.2, 131.0, 130.3, 129.1, 128.3, 128.2, 127.2, 122.2, 116.2, 116.2, 56.8, 38.5, 31.6, 26.3, 23.7, 14.1; HRMS (ESI) [M + H]+ m/z 393.2168 (calcd. for C24H29N2O3, 393.2178). Synthesis of compounds 6b-7b In general, to a solution of pyridine (0.5 ml) was added the corresponding L-amino acid esters (0.035 mmol), 5b (5 mg, 0.023 mmol), and EDCI (4.8 mg, 0.025 mmol). The mixture was stirred at room temperature overnight, and then the pH was adjusted to 3–4 with 1 N HCl. The mixture was extracted with ethyl acetate and concentrated under vacuum. The residue was purified by flash column (petroleum ether: ethyl acetate = 2:1) to afford compounds 6b-7b, respectively. Compound 6b: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.89 (d, J = 15.6, 1H), 7.54 (d, J = 7.6, 1H), 7.44 (d, J = 7.7, 1H), 7.30 (t, J = 7.3, 1H), 7.22 (t, J = 7.6, 1H), 7.04 (d, J = 8.4, 2H), 6.74 (d, J = 14.9, 1H), 6.71 (d, J = 8.4, 2H), 6.53 (d, J = 15.6, 1H), 6.11 (dt, J = 15.5, 7.0, 1H), 4.73 (dd, J = 8.3, 6.0, 1H), 3.70 (s, 3H), 3.10 (dd, J = 13.9, 5.9, 1H), 2.95 (dd, J = 13.9, 8.4, 1H), 2.25 (q, J = 7.3, 6.8, 2H), 1.54 (m, 2H), 0.99 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 173.7, 168.4, 157.5, 140.4, 139.5, 136.1, 133.6, 131.2, 131.2, 130.7, 128.7, 128.3, 128.2, 128.0, 127.6, 122.5, 116.3, 116.3, 55.8, 52.7, 37.8, 36.5, 23.6, 14.1; HRMS (ESI) [M + H]+ m/z 394.2015 (calcd. for C24H28NO4, 394.2018). Compound 7b: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.90 (d, J = 15.7, 1H), 7.55 (d, J = 7.0, 1H), 7.44 (d, J = 7.4, 1H), 7.30 (t, J = 7.5, 1H), 7.23 (t, J = 7.6, 1H), 7.05 (d, J = 8.5, 2H), 6.74 (d, J = 15.2, 1H), 6.71 (d, J = 8.5, 2H), 6.54 (d, J = 15.6, 1H), 6.11 (dt, J = 15.5, 7.0, 1H), 4.71 (dd, J = 8.2, 6.3, 1H), 4.15 (q, J = 7.1, 2H), 3.08 (dd, J = 13.9, 6.2, 1H), 2.96 (dd, J = 13.9, 8.2, 1H), 2.25 (qd, J = 7.1, 1.5, 2H), 1.54 (m, 2H), 1.22 (t, J = 7.1, 3H), 0.99 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 173.3, 168.4, 157.5, 140.3, 139.4, 136.1, 133.6, 131.3, 131.3, 130.7, 128.7, 128.3, 128.2, 128.0, 127.6, 122.6, 116.3, 116.3, 62.3, 55.9, 37.9, 36.5, 23.6, 14.4, 14.1; HRMS (ESI) [M + H]+ m/z 408.2204 (calcd. for C25H30NO4, 408.2175). Synthesis of compounds 6c-8c In general, to a solution of pyridine (1.5 ml) was added the corresponding L-amino acid esters (0.070 mmol), 5c (15 mg, 0.069 mmol), and EDCI (14.59 mg, 0.076 mmol). The mixture was stirred at room temperature overnight, and then the pH was adjusted to 3–4 with 1 N HCl. The mixture was extracted with ethyl acetate and concentrated under vacuum. The residue was purified by preparative reversed-phase HPLC (acetonitrile: H2O = 55%) to afford compounds 6c-8c, respectively. Compound 6c: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.88 (d, J = 15.6, 1H), 7.58 (d, J = 7.1, 1H), 7.27 (t, J = 7.4, 1H), 7.20 (m, 2H), 7.04 (d, J = 8.5, 2H), 6.71 (d, J = 8.5, 2H), 6.56 (d, J = 15.6, 1H), 4.74 (dd, J = 8.3, 5.9, 1H), 3.70 (s, 3H), 3.10 (dd, J = 13.9, 6.0, 1H), 2.96 (dd, J = 13.9, 8.3, 1H), 2.73 (m, 2H), 1.54 (m, 2H), 1.34 (m, 4H), 0.89 (t, J = 6.9, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 173.7, 168.5, 157.5, 143.6, 140.1, 134.4, 131.2, 131.2, 131.2, 130.7, 128.7, 127.4, 127.3, 122.1, 116.3, 116.3, 55.8, 52.7, 37.8, 34.2, 32.7, 32.6, 23.6, 14.4; ESIMS [M + H]+ m/z 395.8 (calcd. for C24H30NO4, 396.2). Compound 7c: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.88 (d, J = 15.6, 1H), 7.58 (d, J = 7.2, 1H), 7.27 (t, J = 6.7, 1H), 7.20 (m, 2H), 7.05 (d, J = 8.5, 2H), 6.71 (d, J = 8.5, 2H), 6.57 (d, J = 15.6, 1H), 4.71 (dd, J = 8.1, 6.3, 1H), 4.15 (q, J = 7.0, 2H), 3.08 (dd, J = 13.9, 6.3, 1H), 2.96 (dd, J = 13.9, 8.2, 1H), 2.74 (m, 2H), 1.54 (m, 2H), 1.34 (m, 4H), 1.22 (t, J = 7.1, 3H), 0.90 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 173.3, 168.5, 157.5, 143.6, 140.1, 134.4, 131.3, 131.3, 131.2, 130.7, 128.7, 127.4, 127.3, 122.2, 116.3, 116.3, 62.3, 55.9, 37.9, 34.2, 32.7, 32.6, 23.5, 14.4, 14.3; HRMS (ESI) [M + H]+ m/z 410.2330 (calcd. for C25H32NO4, 410.2331). Compound 8c: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.88 (d, J = 15.6, 1H), 7.59 (d, J = 7.2, 1H), 7.27 (t, J = 7.4, 1H), 7.20 (m, 2H), 7.07 (d, J = 8.5, 2H), 6.71 (d, J = 8.5, 2H), 6.57 (d, J = 15.6, 1H), 4.62 (m, 1H), 3.04 (dd, J = 13.9, 6.7, 1H), 2.94 (dd, J = 13.9, 8.0, 1H), 2.74 (m, 2H), 1.55 (m, 2H), 1.41 (s, 9H), 1.34 (m, 4H), 0.90 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 172.5, 168.4, 157.4, 143.6, 140.0, 134.5, 131.4, 131.4, 131.1, 130.7, 128.9, 127.4, 127.3, 122.4, 116.2, 116.2, 82.9, 56.5, 38.0, 34.2, 32.7, 32.6, 28.2, 28.2, 28.2, 23.5, 14.4; HRMS (ESI) [M-H]- m/z 436.2479 (calcd. for C27H34NO4, 436.2488). Synthesis of compound 10 To a solution of pyridine (2 ml) was added the 2-naphthoic acid (9) (15 mg, 0.087 mmol), L-tyrosine methyl ester (25.5 mg, 0.13 mmol), and EDCl (18.4 mg, 0.096 mmol). The mixture was stirred at room temperature overnight, and then the pH was adjusted to 3–4 with 1 N HCl. The mixture was extracted with ethyl acetate and concentrated under vacuum. The residue was purified by flash column (petroleum ether: ethyl acetate = 2:1) to afford compound 10 as a light-yellow oil (26 mg, 85.60%). Compound 10: 1H NMR (ppm, 400 MHz, CD3OD): δ 8.28 (s, 1H), 7.93 (dd, J = 7.5, 1.7, 1H), 7.89 (dd, J = 7.9, 3.2, 2H), 7.79 (dd, J = 8.6, 1.8, 1H), 7.55 (m, 2H), 7.10 (d, J = 8.5, 2H), 6.72 (d, J = 8.5, 2H), 4.85 (m, 1H), 3.73 (s, 3H), 3.22 (dd, J = 13.9, 5.8, 1H), 3.07 (dd, J = 13.9, 9.1, 1H); 13C NMR (ppm, 100 MHz, CD3OD): δ 173.9, 170.3, 157.4, 136.3, 133.9, 132.4, 131.3, 131.3, 130.0, 129.3, 129.1, 129.0, 128.9, 128.8, 127.8, 124.9, 116.3, 116.3, 56.3, 52.7, 37.5; HRMS (ESI) [M + H]+ m/z 350.1385 (calcd. for C21H20NO4, 350.1392). Synthesis of compound 13 A suspension of homo-L-tyrosine, hydrobromide (50 mg, 0.181 mmol) in MeOH (1.5 ml) was stirred at −20 °C for 20 min. Thionyl chloride (40 μL, 0.543 mmol) was added dropwise to the reaction mixture. The mixture was stirred at room temperature overnight and then quenched with H2O. The mixture was extracted with ethyl acetate. The organic layers were combined and concentrated in vacuo. The residue was subjected to flash chromatography (200 − 300 mesh) to afford compound 12 (10 mg, 26.4%). To a solution of pyridine (1 ml) was added the 5a (5.4 mg, 0.025 mmol), compound 12 (8 mg, 0.038 mmol), and EDCl (5.28 mg, 0.0275 mmol). The mixture was stirred at room temperature overnight, and then the pH was adjusted to 3–4 with 1 N HCl. The mixture was extracted with ethyl acetate and concentrated under vacuum. The residue was purified by flash column (petroleum ether: ethyl acetate = 2:1) to afford compound 13 as a white solid (7 mg, 68.76%). Compound 13: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.81 (d, J = 15.8, 1H), 7.68 (d, J = 7.5, 1H), 7.34 (t, J = 7.4, 1H), 7.30 (t, J = 7.5, 1H), 7.21 (d, J = 7.3, 1H), 7.01 (d, J = 8.5, 2H), 6.70 (d, J = 8.6, 2H), 6.65 (d, J = 15.7, 1H), 6.59 (d, J = 11.2, 1H), 5.83 (dt, J = 11.5, 7.5, 1H), 4.48 (dd, J = 9.2, 4.9, 1H), 3.71 (s, 3H), 2.62 (m, 2H), 2.12 (m, 1H), 2.01 (m, 3H), 1.41 (m, 2H), 0.86 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 174.3, 168.7, 156.8, 140.9, 139.5, 135.9, 134.5, 132.7, 131.1, 130.5, 130.5, 130.3, 128.3, 128.2, 127.2, 122.0, 116.3, 116.3, 53.5, 52.7, 34.8, 32.2, 31.6, 23.7, 14.2; HRMS (ESI) [M + H]+ m/z 408.2177 (calcd. for C25H30NO4, 408.2175). Synthesis of compound 14 To a solution of pyridine (1 ml) was added the 5a (10 mg, 0.046 mmol), L-3,4-dihydroxyphenylalanine methyl ester hydrochloride (17.09 mg, 0.069 mmol), and EDCl (9.72 mg, 0.0506 mmol). The mixture was stirred at room temperature overnight, and then the pH was adjusted to 3–4 with 1 N HCl. The mixture was extracted with ethyl acetate and concentrated under vacuum. The residue was purified by flash column (petroleum ether: ethyl acetate = 2:1) to afford compound 14 as a light-yellow solid (13.28 mg, 70.55%). Compound 14: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.75 (d, J = 15.8, 1H), 7.65 (d, J = 7.5, 1H), 7.33 (t, J = 7.4, 1H), 7.27 (t, J = 7.5, 1H), 7.19 (d, J = 7.5, 1H), 6.68 (d, J = 8.0, 1H), 6.65 (d, J = 2.0, 1H), 6.59 (d, J = 15.7, 1H), 6.56 (d, J = 11.3, 1H), 6.53 (dd, J = 8.1, 2.1, 1H), 5.84 (dt, J = 11.5, 7.4, 1H), 4.71 (dd, J = 8.1, 6.0, 1H), 3.70 (s, 3H), 3.03 (dd, J = 13.9, 6.0, 1H), 2.90 (dd, J = 13.9, 8.1, 1H), 1.99 (qd, J = 7.4, 1.7, 2H), 1.40 (m, 2H), 0.84 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 173.7, 168.4, 146.3, 145.3, 140.8, 139.5, 135.8, 134.4, 131.1, 130.3, 129.4, 128.3, 128.2, 127.2, 121.9, 121.6, 117.2, 116.3, 55.8, 52.6, 38.0, 31.6, 23.6, 14.1; HRMS (ESI) [M + H]+ m/z 410.1961 (calcd. for C24H28NO5, 410.1967). Synthesis of compound 15 To a solution of pyridine (1 ml) was added the 5c (10 mg, 0.046 mmol), L-3,4-dihydroxyphenylalanine methyl ester hydrochloride (17.09 mg, 0.069 mmol), and EDCl (9.72 mg, 0.0506 mmol). The mixture was stirred at room temperature overnight, and then the pH was adjusted to 3–4 with 1 N HCl. The mixture was extracted with ethyl acetate and concentrated under vacuum. The residue was purified by flash column (petroleum ether: ethyl acetate = 1.5:1) to afford compound 15 as a light-yellow solid (13.50 mg, 71.37%). Compound 15: 1H NMR (ppm, 400 MHz, CD3OD): δ 7.89 (d, J = 15.6, 1H), 7.58 (d, J = 7.2, 1H), 7.27 (t, J = 7.4, 1H), 7.20 (m, 2H), 6.68 (d, J = 8.0, 1H), 6.66 (d, J = 2.0, 1H), 6.57 (d, J = 15.6, 1H), 6.53 (dd, J = 8.0, 2.0, 1H), 4.73 (dd, J = 8.0, 6.1, 1H), 3.71 (s, 3H), 3.03 (dd, J = 13.9, 6.0, 1H), 2.91 (dd, J = 13.9, 8.1, 1H), 2.74 (m, 2H), 1.55 (m, 2H), 1.34 (m, 4H), 0.90 (t, J = 7.4, 3H); 13C NMR (ppm, 100 MHz, CD3OD): δ 173.7, 168.5, 146.3, 145.4, 143.6, 140.1, 134.4, 131.2, 130.7, 129.4, 127.4, 127.3, 122.1, 121.6, 117.2, 116.3, 55.8, 52.7, 38.1, 34.2, 32.7, 32.6, 23.5, 14.4; HRMS (ESI) [M + H]+ m/z 412.2121 (calcd. for C24H30NO5, 412.2124). Antibacterial assay in vitro Antimicrobial assays were conducted in flat-bottom, sterile 96-well plates (Corning) in triplicate, using a broth microdilution protocol. Penicillin G (Adamas, Shanghai, China; catalogue no. 15306 A) and streptomycin sulphate (Adamas, Shanghai, China; catalogue no. 53237B) were used as positive controls for gram-positive and gram-negative bacteria, respectively. Compounds 6a-8a, 6b-7b, 6c-8c, 10, and 13–15 were tested for antibacterial activity against Staphylococcus aureus ATCC6538 (Biobw, Beijing, China; catalogue no. bio-67395) and Bacillus subtilis ATCC6633 (Biobw, Beijing, China; catalogue no. bio-67377). Compound 14 was also tested for antibacterial activity against MRSA ATCC43300 (Biobw, Beijing, China; catalogue no. bio-72665), MRSA 1593 (multidrug-resistant strain, environmentally isolated from the door handle of the ward) and Enterococcus faecalis ATCC 51299 (Biobw, Beijing, China; catalogue no. bio-72812) using vancomycin (Adamas, Shanghai, China; catalogue no. 22963B) as a positive control. Briefly, the bacteria were cultured on an LB agar plate and incubated overnight at 28 °C, and then transferred into 50 ml of LB medium in a 250 ml flask and cultured for 5 h at 28 °C. The cells were suspended in the same medium to produce a suspension of 1 × 106 CFU/mL, which was then added into each well (99 μL/well) in a 96-well plate. Subsequently, 1 μL of each tested compound was added with a final concentration of 40, 20, 10, 5, and 2.5 μg/mL. The mixture was incubated at 28 °C for 16 h, and the absorption was evaluated at 600 nm with a plate reader. The MIC values were calculated as the lowest concentration of the compound that inhibited bacterial growth. The minimum bactericidal concentration (MBC) value of 14 was calculated as the lowest concentration that yielded no bacterial growth upon subculture onto antibiotic-free agar plates. For the evaluation of the mutant prevention concentration (MPC) value, the MRSA cells were suspended at a concentration of 1 × 1010 CFU/mL. The MPC value was determined as the lowest concentration that yielded no bacterial growth upon subculture onto antibiotic-free agar plates. Colony-forming unit assay The bactericidal activity of 14 against Staphylococcus aureus ATCC6538 was examined by a colony-forming unit assay. The bacteria were treated with 14 at the concentrations of 10, 20, and 40 μg/mL, respectively. After 12 h, the residual bacteria were collected and reseeded into the growth medium, respectively. The colony-forming of each sample was recorded and photographically documented after 36 h. Scanning electron microscopy (SEM) analysis MRSA (ATCC 43300) suspensions treated with 2 or 14 (20 or 40 μg/mL) were cultured at 25 °C and 180 rpm for 2 h. The bacteria were then collected by filtration and washed with phosphate-buffered saline (PBS, pH 7.4). The samples were fixed with 2.5% glutaraldehyde for 6 h and then washed with PBS. Dehydration was carried out with ethanol using a concentration gradient (30%, 50%, 70%, 90%, and 100%, 15 min for each). Finally, the samples were air-dried at room temperature and coated with gold. Microscopic analysis was performed using a scanning electron microscope (HITACHI SU8600, Japan). Reactive oxygen species (ROS) detection assay The Intracellular ROS levels were measured with a detection kit containing a fluorescent probe DCFH-DA (Adamas, Shanghai, China). Bacterial cells were suspended in PBS (pH = 7.2) to a final concentration of 1 × 108 CFU/mL. The suspension was then treated with 14 at a concentration of 20, 40, or 80 μg/mL and incubated at 37 °C for 1 h. Rosup was used as a positive control. The cells were then washed with PBS and incubated with DCFH-DA (10 μM) at 37 °C for 30 min. The intracellular fluorescence intensity was finally recorded using a microplate reader (excitation/emission: 488/525 nm, Cytation 5, BioTek, USA). Antibacterial assay in vivo Galleria mellonella larvae were purchased from Shanghai Payuan Company. The tolerance of the larvae against the injection of MRSA was first evaluated. Distinct doses of MRSA suspension (0.5 × 106 CFU, 1 × 106 CFU, 2 × 106 CFU, 5 × 106 CFU, and 10 × 106 CFU) were inoculated in the last left proleg (10 μL), and the survival rates were recorded at 12-h intervals for 120 h. The final dose was then determined to be 2 × 106 CFU based on the gradient survival rate. In the formal experiment, the larvae were randomly divided into five groups (n = 10 per group): group 1 (negative control); group 2 (positive control, vancomycin-treated, 30 mg/kg); group 3 (compound 14-treated, 50 mg/kg), group 4 (compound 14-treated 25 mg/kg); group 5 (MRSA infected control, vehicle treated). Larvae were inoculated in the last left proleg with 10 μL of MRSA suspension (2 × 106 CFU). The compound was then inoculated via proleg injection immediately. All groups were maintained in sterile Petri dishes at 37 °C with 60% humidity under fasting conditions. Survival rates were recorded at 12-h intervals for 120 h. Kaplan-Meier survival analysis was carried out using GraphPad Prism 9.5.1 with statistical significance. Cytotoxicity assay Cytotoxicity of compound 14 was tested with the CCK-8 (Dojindo, Japan) method. Human HepG2 cells were cultured in a DMEM medium with 10% FBS and 1% penicillin/streptomycin. The cells were first seeded in a 96-well plate (5000–10,000 cells/well) and then incubated for 24 h. Compound 14 with various concentrations was then added, and the cells were incubated for 48 h. The CCK-8 reagent (10 μL/well) was finally added, and the absorbance was recorded at 450 nm. Doxorubicin was used as a positive control. Haemolysis assay The fresh rabbit erythrocytes (Adamas, Shanghai, catalogue no. 041444700) were collected by centrifuging (3000 rpm for 10 min) and repeated washing with PBS (pH 7.4). When the supernatant was clean and colourless, the erythrocytes were suspended in PBS (4% v/v). The test compound (14, DMSO stock) was then added to the erythrocyte suspension (100 μL) with the final concentrations of 12.5, 25, and 50 µM, respectively. The distilled water was used as a positive control. The PBS buffer (pH 7.4) was used as a negative control. The erythrocytes were incubated for 1 h at 37 °C and then centrifuged (3000 rpm for 5 min). The supernatant was collected and suspended in a 96-well plate. The absorbance was measured at 500 nm. The haemolytic activity was calculated by the equation: % haemolytic activity = [(Abs(compound) – Abs(negative control)/(Abs (positive control) – Abs(negative control))] × 100. Tyrosinase activation assay Mushroom tyrosinase was purchased from Shanghai Yuanye Bio-Technology Co., Ltd (catalogue no. S22800-25ku), as a lyophilised powder, and its enzymatic activity was assayed as reported method using L-DOPA (Adamas, Shanghai, China; catalogue no. CY23370C) as a substrate. The enzymatic activity was evaluated by the absorbance of dopachrome at 475 nm. Briefly, all test samples were dissolved in DMSO (Adamas, Shanghai, China; catalogue no. 775927S) and diluted to the stocks of 40, 20, and 4 mg/mL, respectively. DMSO and kojic acid (Adamas, Shanghai, China; catalogue no. 60307B) were used as negative and positive controls, respectively. Each sample (1 μL in DMSO) was first mixed with 29 μL of PBS (pH 7.2) and 20 μL of tyrosinase solution (250 units/ml) in a 96-well plate. The mixture was pre-incubated at 30 °C for 10 min, and then 5 μL of L-DOPA solution (1 mg/mL) in 45 μL of PBS buffer was added. The mixture was incubated for an additional 20 min, and the absorbance was finally recorded with a plate reader at 475 nm. Molecular docking analysis The molecular docking analysis was carried out following the previously established protocols.6 The crystal structure of Agaricus bisporus tyrosinase (AbPPO3) was downloaded from the protein data bank (PDB ID: 2Y9W). Molecular docking was performed with QuickVina-W. The results were visualised with the PyMOL Molecular Graphics System (Version 2.1.0, Schrödinger, LLC). Supplementary Material Revised_Supporting_information_with_track_change_highlighted_Clean.docx